Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.

Yuanchao Shi,Jingwei Duan,Quanlin Guan, Penglong Xue,Ya Zheng

International Immunopharmacology（2020）

引用 7|浏览6

暂无评分

摘要

•All included trials are RCTs.•The survival of different PD-L1 expression groups is evaluated.•The safety of different ICIs is comprehensively evaluated.

查看译文

关键词

Programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) inhibitors,Expression of PD-L1,Non-Small-Lung-cancer,Chemotherapy

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要